共 50 条
- [3] Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation [J]. International Journal of Hematology, 2022, 116 : 315 - 329
- [9] Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (09): : 610 - 616